?
|
Naslov in reference |
Title and reference |
|
Sklep Sveta (EU) 2023/567 z dne 9. marca 2023 o stališču, ki se zastopa v imenu Evropske unije na šestinšestdesetem zasedanju Komisije ZN za droge o vključitvi substance v tabele v okviru Enotne konvencije o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972, in Konvencije o psihotropnih substancah iz leta 1971 Sklep Sveta (EU) 2023/567 z dne 9. marca 2023 o stališču, ki se zastopa v imenu Evropske unije na šestinšestdesetem zasedanju Komisije ZN za droge o vključitvi substance v tabele v okviru Enotne konvencije o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972, in Konvencije o psihotropnih substancah iz leta 1971 ST/6157/2023/INIT
OJ L 74, 13/03/2023, str. 53–57
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Council Decision (EU) 2023/567 of 9 March 2023 on the position to be taken, on behalf of the European Union, in the 66th session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971 Council Decision (EU) 2023/567 of 9 March 2023 on the position to be taken, on behalf of the European Union, in the 66th session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971 ST/6157/2023/INIT
OJ L 74, 13/03/2023, p. 53–57
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
|
Datumi |
Dates |
|
|
|
Drugi podatki |
Miscellaneous information |
|
|
|
Postopek |
Procedure |
|
|
|
Klasifikacije |
Classifications |
|
|
|
Besedilo |
Text |
| 13.3.2023 | SL | Uradni list Evropske unije | L 74/53 | 13.3.2023 | EN | Official Journal of the European Union | L 74/53 |
| SKLEP SVETA (EU) 2023/567 | COUNCIL DECISION (EU) 2023/567 |
| z dne 9. marca 2023 | of 9 March 2023 |
| o stališču, ki se zastopa v imenu Evropske unije na šestinšestdesetem zasedanju Komisije ZN za droge o vključitvi substance v tabele v okviru Enotne konvencije o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972, in Konvencije o psihotropnih substancah iz leta 1971 | on the position to be taken, on behalf of the European Union, in the 66th session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971 |
| SVET EVROPSKE UNIJE JE – | THE COUNCIL OF THE EUROPEAN UNION, |
| ob upoštevanju Pogodbe o delovanju Evropske unije in zlasti člena 83(1) v povezavi s členom 218(9) Pogodbe, | Having regard to the Treaty on the Functioning of the European Union, and in particular Article 83(1), in conjunction with Article 218(9) thereof, |
| ob upoštevanju predloga Evropske komisije, | Having regard to the proposal from the European Commission, |
| ob upoštevanju naslednjega: | Whereas: |
| (1) | Enotna konvencija Združenih narodov (ZN) o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972 (v nadaljnjem besedilu: Konvencija o mamilih), je začela veljati 8. avgusta 1975. | (1) | The United Nations (UN) Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol (‘the Convention on Narcotic Drugs’) entered into force on 8 August 1975. |
| (2) | Na podlagi člena 3 Konvencije o mamilih se lahko Komisija ZN za droge odloči, da v tabele iz navedene konvencije doda nove substance. Tabele lahko spreminja samo v skladu s priporočili Svetovne zdravstvene organizacije (SZO), lahko pa se tudi odloči, da sprememb, ki jih priporoča SZO, ne bo uveljavila. | (2) | Pursuant to Article 3 of the Convention on Narcotic Drugs, the Commission on Narcotic Drugs may decide to add substances to the Schedules of that Convention. It can make changes in the Schedules only in accordance with the recommendations of the World Health Organisation (‘WHO’), but it can also decide not to make the changes recommended by the WHO. |
| (3) | Konvencija ZN o psihotropnih substancah iz leta 1971 (v nadaljnjem besedilu: Konvencija o psihotropnih substancah) je začela veljati 16. avgusta 1976. | (3) | The UN Convention on Psychotropic Substances of 1971 (‘the Convention on Psychotropic Substances’) entered into force on 16 August 1976. |
| (4) | Na podlagi člena 2 Konvencije o psihotropnih substancah se lahko Komisija ZN za droge na podlagi priporočil SZO odloči, da v tabele iz navedene konvencije doda substance ali da jih iz njih črta. Ima široka diskrecijska pooblastila, v okviru katerih lahko upošteva gospodarske, socialne, pravne, upravne in druge dejavnike, ne sme pa ravnati samovoljno. | (4) | Pursuant to Article 2 of the Convention on Psychotropic Substances, the Commission on Narcotic Drugs may decide to add substances to the Schedules of that Convention or to remove them, on the basis of the recommendations of the WHO. It has broad discretionary powers to take into account economic, social, legal, administrative and other factors, but may not act arbitrarily. |
| (5) | Spremembe tabel Konvencije o mamilih in Konvencije o psihotropnih substancah neposredno vplivajo na področje uporabe prava Unije na področju nadzora nad drogami. Okvirni sklep Sveta 2004/757/PNZ (1) se uporablja za substance, navedene v tabelah iz navedenih konvencij. Zato so vse spremembe tabel, priloženih navedenima konvencijama, neposredno vključene v skupna pravila Unije. | (5) | Changes to the Schedules of the Convention on Narcotic Drugs and to the Convention on Psychotropic Substances have direct repercussions for the scope of application of Union law in the area of drug control. Council Framework Decision 2004/757/JHA (1) applies to substances listed in the Schedules of those Conventions. Thus, any change to the Schedules annexed to those Conventions is directly incorporated into common Union rules. |
| (6) | Komisija ZN za droge mora na šestinšestdesetem zasedanju, ki bo potekalo od 13. do 17. marca 2023 na Dunaju, sprejeti sklepe glede vključitve sedmih novih substanc v tabele Konvencije o mamilih in Konvencije o psihotropnih substancah. | (6) | During its 66th session, which is scheduled for 13 to 17 March 2023 in Vienna, the Commission on Narcotic Drugs is to decide on the addition of seven new substances to the Schedules of the Convention on Narcotic Drugs and of the Convention on Psychotropic Substances. |
| (7) | Unija ni pogodbenica Konvencije o mamilih ali Konvencije o psihotropnih substancah. Ima status opazovalke brez glasovalne pravice v Komisiji ZN za droge, v kateri bo marca 2023 imelo glasovalno pravico dvanajst držav članic (2). Svet bi moral te države članice pooblastiti, da izrazijo stališče Unije o vključitvi substanc v tabele v okviru teh konvencij, saj take odločitve spadajo v pristojnost Unije. | (7) | The Union is not a party to the Convention on Narcotic Drugs or to the Convention on Psychotropic Substances. It has an observer status with no voting rights in the Commission on Narcotic Drugs, of which 12 Member States are members with the right to vote in March 2023 (2). It is necessary for the Council to authorise those Member States to express the position of the Union on the scheduling of substances under those Conventions as such decisions fall under the competence of the Union. |
| (8) | SZO je priporočila, naj se štiri nove substance dodajo v Tabelo I Konvencije o mamilih in trinove substance v Tabelo II Konvencije o psihotropnih substancah. | (8) | The WHO has recommended the addition of four new substances to Schedule I of the Convention on Narcotic Drugs, and the addition of three new substances to Schedule II of the Convention on Psychotropic Substances. |
| (9) | Vse substance, ki jih je pregledal Strokovni odbor SZO za odvisnost od drog (v nadaljnjem besedilu: Strokovni odbor) in za katere je SZO priporočila vključitev v tabele, spremlja Evropski center za spremljanje drog in zasvojenosti z drogami (EMCDDA) kot nove psihoaktivne substance pod pogoji iz Uredbe (ES) št. 1920/2006 Evropskega parlamenta in Sveta (3). | (9) | All substances reviewed by the WHO Expert Committee on Drug Dependence (‘the Expert Committee’) and recommended for scheduling by the WHO are monitored by the European Monitoring Centre for Drugs and Drug Addiction (‘EMCDDA’) as new psychoactive substances under the terms of Regulation (EC) No 1920/2006 of the European Parliament and of the Council (3). |
| (10) | Glede na oceno Strokovnega odbora je ADB-BUTINACA (kemijsko ime: N-[1-(aminokarbonil)-2,2-dimetilpropil]-1-butil-1H-indazol-3-karboksamid) sintetični kanabinoid, pridobljen iz indazola, pri čemer je aktivna snov S-enantiomer (št. CAS: 2682867-55-4). ADB-BUTINACA nima nobene terapevtske uporabe in ni pridobil dovoljenja za promet kot zdravilo. Obstajajo zadostni dokazi, da se ADB-BUTINACA zlorablja ali da je verjetno, da se zlorablja, in lahko pomeni javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se ADB-BUTINACA uvrsti v Tabelo II Konvencije o psihotropnih substancah. | (10) | According to the assessment by the Expert Committee, ADB-BUTINACA (IUPAC name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-1H-indazole-3-carboxamide) is an indazole-derived synthetic cannabinoid, the S-enantiomer being the active compound (CAS No.: 2682867-55-4). ADB-BUTINACA has no therapeutic uses and it has not received a medicinal product marketing authorisation. There is sufficient evidence that ADB-BUTINACA is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that ADB-BUTINACA is placed in Schedule II of the Convention on Psychotropic Substances. |
| (11) | ADB-BUTINACA je bil odkrit v 26 državah članicah in je pod nadzorom v vsaj petih državah članicah. ADB-BUTINACA intenzivno spremlja tudi EMCDDA. Zanj je bilo v sistemu zgodnjega obveščanja in odzivanja Evropske unije (EWRS) objavljeno opozorilo, povezano z javnim zdravjem. ADB-BUTINACA je omenjen tudi v dveh drugih opozorilih v zvezi z javnim zdravjem. Povezan je z resnimi neželenimi dogodki, vključno s 14 smrtnimi primeri, o katerih sta poročali dve državi članici. | (11) | ADB-BUTINACA has been detected in 26 Member States and is controlled in at least five Member States. ADB-BUTINACA is subject to intensive monitoring by the EMCDDA. It has been the subject of a public-health alert issued by the Early Warning and Response System of the European Union (‘EWRS’). ADB-BUTINACA is also mentioned in two additional public health-related alerts. It has been associated with serious adverse events, including 14 deaths reported by two Member States. |
| (12) | Zato bi moralo biti stališče Unije, da se ADB-BUTINACA doda v Tabelo II Konvencije o psihotropnih substancah. | (12) | Therefore, the position of the Union should be to add ADB-BUTINACA to Schedule II of the Convention on Psychotropic Substances. |
| (13) | Glede na oceno Strokovnega odbora je protonitazen (kemijsko ime: N,N-dietil-5-nitro-2-[(4-propoksifenil)metil]-1-H-benzimidazol-1-etanamin) benzimidazolni opioid. Protonitazen je bil najprej sintetiziran kot alternativa morfiju, vendar nima odobrene terapevtske uporabe. Obstajajo zadostni dokazi, da se protonitazen zlorablja ali da je verjetno, da se zlorablja, in lahko predstavlja javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se protonitazen uvrsti v Tabelo I Konvencije o mamilih. | (13) | According to the assessment of the Expert Committee, protonitazene (IUPAC name: N,N-diethyl-5-nitro-2-[(4-propoxyphenyl)methyl]-1-H-benzimidazole-1-ethanamine) is a benzimidazole opioid. Protonitazene was first synthetized as an alternative to morphine but there is no approved therapeutic use of protonitazene. There is sufficient evidence that protonitazene is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that protonitazene be placed in Schedule I of the Convention on Narcotic Drugs. |
| (14) | Protonitazen je bil odkrit v dveh državah članicah in je pod nadzorom v vsaj treh državah članicah. Protonitazen intenzivno spremlja tudi EMCDDA. EMCDDA niso bile sporočene nobene informacije o resnih neželenih dogodkih, ki vključujejo protonitazen. | (14) | Protonitazene has been detected in two Member States and is controlled in at least three Member States. Protonitazene is subject to intensive monitoring by the EMCDDA. No information on serious adverse events involving protonitazene has been reported to the EMCDDA. |
| (15) | Zato bi moralo biti stališče Unije, da se protonitazen doda v Tabelo I Konvencije o mamilih. | (15) | Therefore, the position of the Union should be to add protonitazene to the Schedule I of the Convention on Narcotic Drugs. |
| (16) | Glede na oceno Strokovnega odbora je etazen (kemijsko ime: 2-[(4-etoksifenil)metil]-N,N-dietil-1H-benzimidazol-1-etanamin) sintetični opioid, pridobljen iz benzimidazola, s kemijsko strukturo in farmakološkimi lastnostmi, podobnimi drogam iz Tabele I (na podlagi Konvencije o mamilih), kot so klonitazen, etonitazen in izotonitazen. Etazen so proučevali zaradi analgetičnih lastnosti, vendar nima znane medicinske uporabe. Obstajajo zadostni dokazi, da se etazen zlorablja ali da je verjetno, da se zlorablja, in lahko predstavlja javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se etazen uvrsti v Tabelo I Konvencije o mamilih. | (16) | According to the assessment of the Expert Committee, etazene (IUPAC name: 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1H-benzimidazole-1-ethanamine) is a benzimidazole-derived synthetic opioid with a chemical structure and pharmacological similar to drugs scheduled under Schedule I (under the Convention on Narcotic Drugs) such as clonitazene, etonitazene and isotonitazene. Etazene was studied for its analgesic properties but there is no known medical use of etazene. There is sufficient evidence that etazene is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that etazene be placed in Schedule I of the Convention on Narcotic Drugs. |
| (17) | Etazen je bil odkrit v osmih državah članicah in je pod nadzorom v vsaj petih državah članicah. Etazen intenzivno spremlja tudi EMCDDA. Povezan je z resnimi neželenimi dogodki, vključno s štirimi smrtnimi primeri, o katerih sta poročali dve državi članici. | (17) | Etazene has been detected in eight Member States and is controlled in at least five Member States. Etazene is subject to intensive monitoring by the EMCDDA. It has been associated with serious adverse events, including four deaths, reported by two Member States. |
| (18) | Zato bi moralo biti stališče Unije, da se etazen doda v Tabelo I Konvencije o mamilih. | (18) | Therefore, the position of the Union should be to add etazene to the Schedule I of the Convention on Narcotic Drugs. |
| (19) | Glede na oceno Strokovnega odbora je etonitazepin (kemijsko ime: 2-[(4-etoksifenil)metil]-5-nitro-1-(2-pirolidin-1-iletil)-1H-benzoimidazol) sintetični opioid, pridobljen iz benzimidazola, s kemijsko strukturo in farmakološkimi lastnostmi, podobnimi drogam iz Tabele I (na podlagi Konvencijeo mamilih), kot je etonitazen. Etonitazepin so proučevali zaradi analgetičnih lastnosti, vendar nima znane medicinske uporabe. Obstajajo zadostni dokazi, da se etonitazepin zlorablja ali da je verjetno, da se zlorablja, in lahko predstavlja javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se etonitazepin uvrsti v Tabelo I Konvencije o mamilih. | (19) | According to the assessment of the Expert Committee, etonitazepyne (IUPAC name: 2-[(4-ethoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzoimidazole) is a benzimidazole-derived synthetic opioid with a chemical structure and pharmacological similar to drugs scheduled under Schedule I (under the Convention on Narcotic Drugs) such as etonitazene. Etonitazepyne was studied for its analgesic properties but there is no known medical use of etonitazepyne. There is sufficient evidence that etonitazepyne is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that etonitazepyne be placed in Schedule I of the Convention on Narcotic Drugs. |
| (20) | Etonitazepin je bil odkrit v šestih državah članicah in je pod nadzorom v vsaj dveh državah članicah. Podobno kot drugi novi opioidi se lahko etonitazepin prodaja kot nadomestek za nadzorovane opioide in je bilo zanj v EWRS objavljeno opozorilo, povezano z javnim zdravjem. Etonitazepin intenzivno spremlja tudi EMCDDA. O smrtnem primeru s potrjeno izpostavljenostjo etonitazepinu je poročala ena država. | (20) | Etonitazepyne has been detected in six Member States and is controlled in at least two Member States. Similar to other new opioids, etonitazepyne may be sold as a replacement to controlled opioids, and has been the subject of a public health-related alert issued by the EWRS. Etonitazepyne is subject to intensive monitoring by the EMCDDA. A death with confirmed exposure to etonitazepyne has been reported by one country. |
| (21) | Zato bi moralo biti stališče Unije, da se etonitazepin doda v Tabelo I Konvencije o mamilih. | (21) | Therefore, the position of the Union should be to add etonitazepyne to the Schedule I of the Convention on Narcotic Drugs. |
| (22) | Glede na oceno Strokovnega odbora je 2-metil-AP-237 (kemijsko ime: 1-{2-metil-4-[(2E)-3-fenilprop-2-en-1-il]piperazin-1-il}butan-1-on) sintetični opioid, ki se običajno uvršča med 1-cinamilpiperazine. 2-metil-AP-237 nima nobene znane terapevtske uporabe in ni pridobil dovoljenja za promet kot zdravilo. Obstajajo zadostni dokazi, da se 2-metil-AP-237 zlorablja ali da je verjetno, da se zlorablja, in to lahko predstavlja javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se 2-metil-AP-237 uvrsti v Tabelo I Konvencije o mamilih. | (22) | According to the assessment of the Expert Committee, 2-methyl-AP-237 (IUPAC name: 1-{2-methyl-4-[(2E)-3-phenylprop-2-en-1-yl]piperazin-1-yl}butan-1-one) is a synthetic opioid typically classed as a 1-cinnamylpiperazine. There is no known therapeutic use for 2-methyl-AP-237, nor has it received a medicinal product marketing authorisation. There is sufficient evidence that 2-methyl-AP-237 is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that 2-methyl-AP-237 be placed in Schedule I of the Convention on Narcotic Drugs. |
| (23) | 2-metil-AP-237 je bil odkrit v šestih državah članicah in je pod nadzorom v vsaj štirih državah članicah. Povezan je z resnimi neželenimi dogodki, tudi s smrtnim primerom. | (23) | 2-Methyl-AP-237 has been detected in six Member States and is controlled in at least four Member States. It has been associated with serious adverse events, including a death. |
| (24) | Zato bi moralo biti stališče Unije, da se 2-metil-AP-237 doda v Tabelo I Konvencije o mamilih. | (24) | Therefore, the position of the Union should be to add 2-methyl-AP-237 to the Schedule I of the Convention on Narcotic Drugs. |
| (25) | Glede na oceno Strokovnega odbora spada alfa-PiHP (α-PiHP, kemijsko ime: 4-metil-1-fenil-2-(pirolidin-1-il)pentan-1-on) med sintetične katinone. Alfa-PiHP nima nobene znane terapevtske uporabe in ni pridobil dovoljenja za promet kot zdravilo. Obstajajo zadostni dokazi, da se alfa-PiHP zlorablja ali da je verjetno, da se zlorablja, in to lahko predstavlja javni zdravstveni in družbeni problem, kar upravičuje uvedbo mednarodnega nadzora za to substanco. Zato SZO priporoča, da se alfa-PiHP uvrsti v Tabelo II Konvencije o psihotropnih substancah. | (25) | According to the assessment of the Expert Committee, alpha-PiHP (α-PiHP, IUPAC name: 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one) is a synthetic cathinone. There is no known therapeutic use for alpha-PiHP, nor has it received a medicinal product marketing authorisation. There is sufficient evidence that alpha-PiHP is being or is likely to be abused and that it may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that alpha-PiHP be placed in Schedule II of the Convention on Psychotropic Substances. |
| (26) | Alfa-PiHP je bil odkrit v 18 državah članicah in je pod nadzorom v vsaj sedmih državah članicah. Zanj je bilo v EWRS objavljeno opozorilo, povezano z javnim zdravjem. Povezan je z resnimi neželenimi dogodki, vključno s štirimi smrtnimi primeri, o katerih je poročala ena država članica, in je bil odkrit v bioloških vzorcih, povezanih z resnimi neželenimi dogodki, o katerih so poročale štiri države članice. | (26) | Alpha-PiHP has been detected in 18 Member States and is controlled in at least seven Member States. Alpha-PiHP is mentioned in a public health-related alert issued by the EWRS. It has been associated with serious adverse events, including four deaths, reported by one Member State and detected in biological samples linked to serious adverse events, reported by four Member States. |
| (27) | Zato bi moralo biti stališče Unije, da se alfa-PiHP doda v Tabelo II Konvencije o psihotropnih substancah. | (27) | Therefore, the position of the Union should be to add alpha-PiHP to the Schedule II of the Convention on Psychotropic Substances. |
| (28) | Glede na oceno Strokovnega odbora je 3-metilmetkatinon (3-MMC, kemijsko ime: 2-(metilamino)-1-(3-metilfenil)propan-1-on) sintetični katinon in pozicijski izomer mednarodno nadzorovanega 4-metilmetkatinona (4-MMC, mefedron, Tabela II Konvencije o psihotropnih substancah). 3-MMC je bil leta 2016 kritično pregledan, vendar je bilo sklenjeno, da se zahteva še en kritični pregled, ki bo obravnavan na naslednjem zasedanju, ko bo na voljo več informacij. Ugotovljene so bile nekatere patentne prijave, ki vključujejo uporabo 3-MMC, vendar slednji trenutno nima v kliničnih študijah ugotovljene terapevtske uporabe. Prav tako 3-MMC v Uniji nima nobene priznane medicinske ali veterinarske uporabe. | (28) | According to the assessment of the Expert Committee, 3-methylmethcathinone (3-MMC, IUPAC name: 2-(methylamino)-1-(3-methylphenyl)propan-1-one) is a synthetic cathinone and a positional isomer of the internationally controlled 4-methylmethcathinone (4-MMC, mephedrone, Schedule II of the Convention on Psychotropic Substances). 3-MMC was critically reviewed in 2016, but it was decided to request another critical review, to be considered at a subsequent meeting, pending the availability of more information. Some patent applications including the use of 3-MMC were found but no current clinical trials were identified on therapeutic use of 3-MMC. 3-MMC also has no recognised human or veterinary medical use in the Union. |
| (29) | Tveganja 3-MMC je ocenil znanstveni odbor EMCDDA, substanca pa je že bila na podlagi Delegirane direktive Komisije (EU) 2022/1326 (4) vključena v opredelitev pojma „prepovedana droga“ z Okvirnim sklepom 2004/757/PNZ. 3-MMC intenzivno spremlja tudi EMCDDA. V času ocene tveganja novembra 2021 je bil 3-MMC odkrit v 23 državah članicah. Pet držav članic je poročalo o 27 smrtnih primerih s potrjeno izpostavljenostjo 3-MMC, štiri države članice pa so poročale o 14 akutnih zastrupitvah brez smrtnega izida s potrjeno izpostavljenostjo 3-MMC. | (29) | The risks of 3-MMC have been assessed by the scientific committee of the EMCDDA and 3-MMC has already been included in the definition of ‘drug’ under Framework Decision 2004/757/JHA by Commission Delegated Directive (EU) 2022/1326 (4). 3-MMC is subject to intensive monitoring by the EMCDDA. At the time of risk assessment, in November 2021, 3-MMC had been detected in 23 Member States. A total of 27 deaths with confirmed exposure to 3-MMC had been reported by five Member States and 14 acute non-fatal poisonings with confirmed exposure to 3-MMC had been reported by four Member States. |
| (30) | Zato bi moralo biti stališče Unije, da se 3-MMC doda v Tabelo II Konvencije o psihotropnih substancah. | (30) | Therefore, the position of the Union should be to add 3-MMC to the Schedule II of the Convention on Psychotropic Substances. |
| (31) | Primerno je določiti stališče, ki se v imenu Unije zastopa v Komisiji ZN za droge, saj bodo sklepi o vključitvi v tabele v zvezi s temi sedmimi substancami neposredno vplivali na vsebino prava Unije, in sicer na Okvirni sklep 2004/757/PNZ. | (31) | It is appropriate to establish the position to be taken on behalf of the Union in the Commission on Narcotic Drugs, as the decisions on scheduling as regards the seven substances will directly influence the content of Union law, namely Framework Decision 2004/757/JHA. |
| (32) | Stališče Unije izrazijo države članice, ki so članice Komisije ZN za droge, pri čemer nastopijo skupaj. | (32) | The position of the Union is to be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly. |
| (33) | Okvirni sklep 2004/757/PNZ je za Dansko zavezujoč, zato Danska sodeluje pri sprejetju in uporabi tega sklepa. | (33) | Denmark is bound by Framework Decision 2004/757/JHA and is therefore taking part in the adoption and application of this Decision. |
| (34) | Okvirni sklep 2004/757/PNZ je za Irsko zavezujoč, zato Irska sodeluje pri sprejetju in uporabi tega sklepa – | (34) | Ireland is bound by Framework Decision 2004/757/JHA and is therefore taking part in the adoption and application of this Decision, |
| SPREJEL NASLEDNJI SKLEP: | HAS ADOPTED THIS DECISION: |
| Člen 1 | Article 1 |
| Stališče, ki ga v imenu Unije zastopajo države članice na šestinšestdesetem zasedanju Komisije ZN za droge, ki poteka od 13. do 17. marca 2023, ko naj bi navedeni organ sprejel sklepe o vključitvi dodatnih substanc v tabele Enotne konvencije Združenih narodov o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972, in Konvencije Združenih narodov o psihotropnih substancah iz leta 1971, je v skladu s stališčem, določenim v Prilogi k temu sklepu. | The position to be taken on behalf of the Union by the Member States in the 66th session of the Commission on Narcotic Drugs, which takes place from 13 to 17 March 2023, when that body is called upon to adopt decisions on the addition of substances to the Schedules of the United Nations Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the United Nations Convention on Psychotropic Substances of 1971, shall be that set out in the Annex to this Decision. |
| Člen 2 | Article 2 |
| Stališče iz člena 1 izrazijo države članice, ki so članice Komisije ZN za droge, pri čemer nastopijo skupaj v interesu Unije. | The position referred to in Article 1 shall be expressed by the Member States that are members of the Commission of Narcotic Drugs, acting jointly in the interest of the Union. |
| Člen 3 | Article 3 |
| Ta sklep je naslovljen na države članice v skladu s Pogodbama. | This Decision is addressed to the Member States in accordance with the Treaties. |
| V Bruslju, 9. marca 2023 | Done at Brussels, 9 March 2023. |
| Za Svet | For the Council |
| predsednik | The President |
| G. STRÖMMER | G. STRÖMMER |
| (1) Okvirni sklep Sveta 2004/757/PNZ z dne 25. oktobra 2004 o opredelitvi minimalnih določb glede elementov kaznivih dejanj in kazni na področju nedovoljenega prometa s prepovedanimi drogami (UL L 335, 11.11.2004, str. 8). | (1) Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335, 11.11.2004, p. 8). |
| (2) Avstrija, Belgija, Francija, Italija, Litva, Madžarska, Nemčija, Nizozemska, Poljska, Slovenija, Španija in Švedska. | (2) Austria, Belgium, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Slovenia, Spain, and Sweden. |
| (3) Uredba (ES) št. 1920/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 o Evropskem centru za spremljanje drog in zasvojenosti z drogami (UL L 376, 27.12.2006, str. 1). | (3) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction (OJ L 376, 27.12.2006, p. 1). |
| (4) Delegirana direktiva Komisije (EU) 2022/1326 z dne 18. marca 2022 o spremembi Priloge k Okvirnemu sklepu Sveta 2004/757/PNZ v zvezi z vključitvijo novih psihoaktivnih snovi v opredelitev pojma „prepovedana droga“ (UL L 200, 29.7.2022, str. 148). | (4) Commission Delegated Directive (EU) 2022/1326 of 18 March 2022 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of ‘drug’ (OJ L 200, 29.7.2022, p. 148). |
| PRILOGA | ANNEX |
| Stališče, ki ga zastopajo države članice, ki so članice Komisije ZN za droge, pri čemer nastopijo skupaj v interesu Unije, na šestinšestdesetem zasedanju Komisije ZN za droge, ki poteka od 13. do 17. marca 2023 o vključitvi substanc v tabele: | Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union during the 66th session of the Commission on Narcotic Drugs, which takes place from 13 to 17 March 2023, on the scheduling of substances: |
| (1) | ADB-BUTINACA je treba vključiti v Tabelo II Konvencije o psihotropnih substancah, | (1) | ADB-BUTINACA is to be included in Schedule II of the Convention on Psychotropic Substances. |
| (2) | protonitazen je treba vključiti v Tabelo I Konvencije o mamilih, | (2) | Protonitazene is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (3) | etazen je treba vključiti v Tabelo I Konvencije o mamilih, | (3) | Etazene is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (4) | etonitazepin je treba vključiti v Tabelo I Konvencije o mamilih, | (4) | Etonitazepyne is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (5) | 2-metil-AP-237 je treba vključiti v Tabelo I Konvencije o mamilih, | (5) | 2-methyl-AP-237 is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (6) | alfa-PiHP je treba vključiti v Tabelo II Konvencije o psihotropnih substancah, | (6) | Alpha-PiHP is to be included in the Schedule II of the Convention on Psychotropic Substances. |
| (7) | 3-MMC je treba vključiti v Tabelo II Konvencije o psihotropnih substancah. | (7) | 3-MMC is to be included in the Schedule II of the Convention on Psychotropic Substances. |